2026-04-17T07:38:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/127392025-05-03T03:20:48Zcom_2072_378070com_2072_378040col_2072_378092

2025-05-03T03:20:48Z urn:hdl:11351/12739 Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review Balconi, Francesca Garcia-Alvarez, Alejandro Hernando, Jorge OConnor, Juan Manuel Chacon, Matias Tissera, Natalia Soledad Capdevila Castillon, Jaume Aparell digestiu - Càncer - Quimioteràpia Aparell digestiu - Prevenció Tumors neuroendocrins DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors::Carcinoma, Neuroendocrine Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Maintenance Chemotherapy ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos::carcinoma neuroendocrino Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::quimioterapia de mantenimiento First-line chemotherapy; Maintenance therapy; Neuroendocrine carcinoma Quimioterapia de primera línea; Terapia de mantenimiento; Carcinoma neuroendocrino Quimioteràpia de primera línia; Teràpia de manteniment; Carcinoma neuroendocrí Neuroendocrine carcinomas are rare and aggressive malignancies, often diagnosed at advanced stages, leading to poor prognosis. Platinum-based chemotherapy is the standard first-line treatment for advanced neuroendocrine carcinomas; however after achieving response no consensus exists on maintenance therapies and the results are inconsistent. This review examines the role of maintenance therapy following response to first-line chemotherapy in gastroenteropancreatic neuroendocrine carcinomas. We identified limited supporting evidence, primarily from phase II trials and case reports, that suggested maintenance therapy could be considered for prolonging progression-free survival, balancing toxicity, and maintaining quality of life. Nevertheless, prospective studies are needed to validate its clinical efficacy. 2025-05-03T03:20:48Z 2025-05-03T03:20:48Z 2025-03-11T09:43:46Z 2025-03-11T09:43:46Z 2024 2025-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/12739 Cancer Treatment Reviews;132 https://doi.org/10.1016/j.ctrv.2024.102863 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Elsevier Scientia